News >

Ramucirumab/Erlotinib Combo Improves PFS in Frontline EGFR+ NSCLC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Mar 12, 2019

Dr Maura N. Dickler

Maura N. Dickler, MD

The combination of ramucirumab (Cyramza) and erlotinib (Tarceva) significantly improved progression-free survival (PFS) compared with placebo and erlotinib as a frontline treatment for patients with metastatic EGFR-mutant non–small cell lung cancer (NSCLC), meeting the primary endpoint of the RELAY trial (NCT02411448).1

<.0001).

References

  1. Lilly's Cyramza® (Ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients With Metastatic EGFR-Mutated Non-Small Cell Lung Cancer. Eli Lilly and Company. Published March 12, 2019. https://bit.ly/2UtkdPW. Accessed March 12, 2019.
  2. Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet Oncol. 2014;384(9944):665-673. doi: 10.1016/S0140-6736(14)60845-X.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x